Denali Therapeutics (DNLI) Non-Current Deffered Revenue (2018 - 2022)

Denali Therapeutics (DNLI) has 5 years of Non-Current Deffered Revenue data on file, last reported at $479000.0 in Q4 2022.

• Non-Current Deffered Revenue for Q4 2022 came in at $479000.0, down 85.9% year-over-year; the trailing twelve-month figure through Dec 2022 was $479000.0 (down 85.9% YoY), and the FY2022 annual result was $479000.0, down 85.9% from the prior year.
• Non-Current Deffered Revenue slipped to $479000.0 in Q4 2022 per DNLI's latest filing, from $3.4 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $49.6 million in Q2 2018 and troughed at $479000.0 in Q4 2022.
• A 5-year average of $24.6 million and a median of $24.5 million in 2018 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2019 and 2022: Non-Current Deffered Revenue jumped 641.23% in 2019, then sank 89.15% in 2022.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $24.5 million in 2018, then soared by 78.35% to $43.8 million in 2019, then slumped by 46.69% to $23.3 million in 2020, then slumped by 85.43% to $3.4 million in 2021, then tumbled by 85.9% to $479000.0 in 2022.
• Business Quant data shows DNLI's Non-Current Deffered Revenue at $479000.0 in Q4 2022, $3.4 million in Q2 2022, and $3.4 million in Q1 2022.